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Abstract
Background: Intravenous gamma globulin (IVGG) is commonly used in the management of acute
myocarditis. The objective of this study was to systematically review the literature evaluating this
practice.
Methods:  We conducted a comprehensive search (electronic databases, trials registries,
conference proceedings, reference lists, contact with authors) to identify studies evaluating the use
of IVGG in adults and children with a clinical or histologically proven diagnosis of myocarditis of
possible viral etiology and symptoms of less than six months duration. Two reviewers
independently screened the searches, applied inclusion criteria, and graded the evidence.
Results: Results were described qualitatively; data were not pooled because only one randomized
controlled trial (RCT) with 62 patients was identified. The RCT showed no benefit with respect to
cardiac function, functional outcome, or event-free survival. A small, uncontrolled trial (n = 10)
showed significant improvement in LVEF from a mean of 24% to 41% 12 months after IVGG in nine
survivors. A retrospective cohort study of pediatric patients showed improvement in cardiac
function and a trend towards improved survival in patients receiving IVGG (n = 21) versus historic
controls (n = 25). Ten case reports and two case series (total n = 21) described improvement in
cardiac function after administration of IVGG; two case reports showed no benefit of IVGG. One
case of hemolytic anemia was attributed to IVGG.
Conclusion:  There is insufficient data from methodologically strong studies to recommend
routine use of IVGG for acute myocarditis. Future randomized studies that take into account the
etiology of acute myocarditis will be required to determine the efficacy of IVGG.
Background
Myocarditis is an inflammatory cardiomyopathy that
occurs in all age groups [1]. Most cases are thought to be
sub-clinical, but myocarditis can manifest as fulminant or
chronic heart failure [2]. The inflammation is presumed
to most commonly start as an infectious process, although
autoimmune and idiopathic forms also occur [1]. Bacte-
rial or protozoal myocarditis is rare in the developed
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world, with the vast majority of cases being viral [3].
Although most viruses that are pathogenic for humans
can cause myocarditis, common etiologic agents are enter-
oviruses and adenoviruses [4]. It remains unclear if the
primary problem in severe disease is ongoing damage
from a virus, a post-infectious inflammatory reaction, or a
combination of both factors. If ongoing infection is the
primary problem, IVGG could be efficacious if it contains
antibodies to the microbe. IVGG also has anti-inflamma-
tory properties that prevent the formation of and down-
regulate cytokines [5] so could be efficacious even if the
primary problem is a post-infectious inflammatory
reaction.
The objective of this study was to review the evidence eval-
uating the use of IVGG in the treatment of patients with
acute myocarditis. A secondary objective was to determine
if there is an identifiable group of acute myocarditis
patients (based on age, duration of symptoms, acuity of
onset of symptoms, cardiac function at presentation, viro-
logic results, or the presence or absence of histologic evi-
dence of acute myocarditis on cardiac biopsy in patients
where a biopsy was performed) who would benefit from
IVGG. The review of randomized controlled trials has
been registered with the Cochrane Collaboration and reg-
ular updates will be available in the Cochrane Library.
Methods
Searching
We systematically searched the following electronic data-
bases: Cochrane Central Register of Controlled Trials (4th
quarter, 2004), MEDLINE (1966 to January Week 4,
2005), EMBASE (1988 to Week 6, 2005), CINAHL (1982
to January Week 3, 2005), Web of Science (1975 to Febru-
ary 5, 2005), and several trial registries in addition to the
Cochrane Heart Group's Trial Registry [6-11]. A compre-
hensive search strategy was developed by a medical
research librarian based on the following terms: immu-
noglobulin, gammaglobulin, ivig, immunoglobulin, igg,
immune, serum, myocarditis, cardiomyopathy, myocardi-
opathy, carditis, heart, inflammation. The complete
search strategy is available from the authors on request.
We also contacted the primary author of the RCT, and
reviewed the reference lists of all selected articles. In addi-
tion, we handsearched proceedings from the following
meetings for RCTs: American Heart Association (1999–
2004), American College of Cardiology (1998–2005),
European Society of Cardiology (1998–2004), and Inter-
national Heart and Lung Transplantation Society (1998–
2004). The search was not limited by language or publica-
tion status.
Study selection
Two reviewers independently screened the searches for
potentially relevant studies. The full manuscript of all
potentially relevant studies was retrieved and each study
was assessed independently by two reviewers for inclusion
using predetermined eligibility criteria. Primary studies of
any design were eligible for inclusion. Inclusion criteria
included reports of patients given IVGG for possible viral
myocarditis within six months of onset of symptoms.
Because of the poor sensitivity of cardiac biopsy as a diag-
nostic tool for acute myocarditis, a histologic diagnosis
was not required. Exclusion criteria included reports of
patients with evidence of ischemic heart disease, rheu-
matic heart disease, or any other non-viral etiology, onset
of myocarditis less than six months postpartum (as the
pathogenesis of postpartum myocarditis may differ from
that of presumed viral myocarditis), or receipt of immu-
nosuppressive therapy (unless this was not possible as
they were reported as part of a case series). Reports of use
of high-dose immunoglobulin directed at specific organ-
isms were excluded as efficacy may be influenced by the
formulation available and the accuracy of the etiologic
diagnosis.
Assessment of methodological quality
Study quality was assessed independently by two review-
ers and discrepancies were resolved by consensus. RCTs
were evaluated using the previously validated Jadad 5-
point score to assess randomization, double blinding, and
losses to follow-up [12]. Allocation concealment was
assessed as adequate, inadequate, or unclear [13]. Non-
RCTs were graded according to the levels of evidence pre-
sented in Table 1.
Data extraction
Data were extracted by one reviewer using a standard form
and checked for accuracy and completeness by a second.
The primary outcome was rate of survival without a trans-
plant or requirement for placement of a left ventricular
assist device. Secondary outcomes included change in
echocardiographic measures of cardiac function, duration
of hospitalization, and improvement in functional symp-
toms (determined by increased exercise tolerance as meas-
ured by any objective test and New York Heart Association
Functional Capacity) when available. Data were collected
on complications and adverse events.
Data analysis
Data from studies that were not RCTs were reported but
not analyzed further. We planned to combine data from
RCTs, to do sub-group analyses, and to test for publica-
tion bias, however these were not possible as only one
RCT was identified. For the RCT, dichotomous data on
efficacy (e.g. event-free survival) were expressed as an
odds ratio (OR) with 95% confidence interval. Dichoto-
mous data on adverse events were reported as a risk differ-
ence and number needed to harm with 95% confidence
intervals. Continuous data (change in left ventricularBMC Cardiovascular Disorders 2005, 5:12 http://www.biomedcentral.com/1471-2261/5/12
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ejection fraction and peak oxygen consumption) were
converted to the mean difference with 95% confidence
intervals. For peak oxygen consumption, we assumed a
correlation of 0.5 and used the methods of Follmann [15]
to calculate the standard deviations of the change from
baseline estimates. Since the number per group was not
given for this variable, an estimate of the sample size in
each group had to be estimated by pro-rating the original
group sample sizes to the new total sample size.
Results
Figure 1 presents a flow diagram of studies considered for
inclusion in the review. Only one RCT evaluating IVGG
for acute myocarditis has been reported to date [16]. The
trial was of moderate methodological quality according to
the Jadad scale (3 out of maximum 5 points, where 5 indi-
cates highest quality); allocation concealment was
unclear. The study enrolled 62 adults (mean age 43.0 +/-
12.3 years; 37 men), of which only ten had cellular
inflammation on endomyocardial biopsy (four fulfilled
the Dallas criteria for acute myocarditis, and three for bor-
derline myocarditis). The authors reported that the given
sample size would provide 80% power to detect a differ-
ence between groups of ≥  8% in ejection fraction (EF)
change scores. Patients were randomized to receive either
2 g/kg IVGG or an equivalent volume of 0.1% albumin in
a blinded fashion. The incidence of death or requirement
for cardiac transplant or placement of a left ventricular
assist device was low in both groups. Event-free survival
was not significantly different but favored the control
group (OR 0.52, 95% CI 0.12, 2.30). Follow-up at 6 and
12 months showed no significant difference in improve-
ment in left ventricular ejection fraction for cases and con-
trols (mean difference 0.00, 95% CI -0.07, 0.07 at six
months; 0.01, 95% CI -0.06, 0.08 at 12 months). Func-
tional capacity as assessed by peak oxygen consumption
was not significantly different in the two groups at 12
months (mean difference -0.80, 95% CI -4.57, 2.97). Infu-
sion-related side effects occurred significantly more often
in the treated group (RD 0.33, 95% CI 0.17, 0.50; number
needed to harm = 3, 95% CI 2, 6), but all appeared to be
mild.
Sixteen additional studies of various designs met the
inclusion criteria [see Additional file 1]. These included a
retrospective case series [17], an uncontrolled trial [18],
two case series [5,19], and twelve case reports [20-31]. In
a retrospective cohort study, Drucker compared children
who were treated with IVGG (n = 21) to historic controls
(n = 26); 65% of the sample was less than two years of age
[17]. The treatment group showed improved cardiac func-
tion and a trend (though not statistically significant)
towards improved survival. McNamara conducted an
uncontrolled trial involving 10 adults (mean age 35.8 +/-
15 years) [18]. One patient with refractory arrhythmias
and severe heart failure died during the infusion; the other
nine patients showed an impressive improvement in car-
diac function following administration of IVGG, with a
significant increase in left ventricular ejection fraction at
12-month follow-up (p = 0.008). In ten case reports and
both case series, improvement in cardiac function was
described after use of IVGG in a total of 21 cases, although
improvement was considered to be minimal in one case
[26]. In the other two case reports, there was no benefit of
IVGG in a patient presenting with hand, foot and mouth
disease and acute myocarditis from coxsackievirus A16
[27] and in a patient with fulminant myocarditis of
unclear etiology [28]. Hemolytic anemia was attributed to
use of IVGG in one case report [26].
We could find no ongoing trials of the use of IVGG in
acute myocarditis, although the European Study of Epide-
miology and Treatment of Cardiac Inflammatory Diseases
(ESETCID) is evaluating hyperimmunoglobulin for
patients with cytomegalovirus-positive myocarditis [32].
Table 1: Levels of evidence for studies of therapeutic interventions from the Oxford Centre for Evidence-based Medicine (website title 
http://www.cebm.net/levels_of_evidence.asp) [14]
Level Study design
1 A Systematic review (with homogeneity) of randomized controlled trials
B Individual randomized controlled trial (with narrow confidence interval)
C All or none
2 A Systematic review (with homogeneity) of cohort studies
B Individual cohort study (including low quality randomized controlled trial, e.g., < 80% follow-up)
C" O u t c o m e s "  r e s e a r c h ; ecological studies
3 A Systematic review (with homogeneity) of case-control studies
B Individual case-control study
4 Case series (and poor quality cohort and case-control studies)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"BMC Cardiovascular Disorders 2005, 5:12 http://www.biomedcentral.com/1471-2261/5/12
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Discussion
The small number of studies evaluating IVGG in the treat-
ment of acute myocarditis reflects the immature state of
this body of literature. We identified only one RCT (Level
1 evidence), which involved 62 adult patients with idio-
pathic cardiomyopathy (of which only 10 had histologic
evidence of myocarditis) and showed no apparent benefit
[9]. This is in contrast to an uncontrolled trial and
Flow diagram of studies considered for inclusion in the review Figure 1
Flow diagram of studies considered for inclusion in the review
Potentially eligible studies identified
and screened (n=2,644)
Studies excluded as not relevant to
study question (n=2,579)
Studies retrieved for detailed
inclusion/exclusion (n=65)
Studies excluded (n=48):
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numerous observational studies (Level 4 evidence), most
of which suggested potential benefit. This indicates a pos-
sible bias towards publication of case reports or case series
with positive results. The validity of evidence was gener-
ally poor, with the majority of included studies ranking
low in terms of level of evidence. The most important
threat to validity for fifteen of the seventeen included
studies was the lack of controls, which could result in an
overestimate of the benefit of IVGG. Spontaneous
improvement in cardiac function is common with acute
myocarditis and can be rapid or gradual, so it is possible
that the improvement noted in these cases was part of the
natural history of the disease. The retrospective cohort
study demonstrated a greater improvement in cardiac
function in patients given IVGG compared to historic con-
trols [17]; this type of study is more susceptible to bias
because of the inability to fully control for all potential
confounders, such as other changes in patient manage-
ment over the eight-year study period.
Acute myocarditis is a relatively non-specific entity, as the
diagnosis is often clinical. Laboratory confirmation con-
sists of microbiologic, histologic, and immunohisto-
chemical methods. With regard to microbiologic
confirmation, it is rare to isolate the etiologic agent from
a myocardial biopsy (probably because the biopsy is usu-
ally done too late in the course of the illness), and identi-
fication of organisms by molecular techniques is in its
infancy [4]. However, with the development of new effec-
tive antivirals, there should be increased efforts towards
making a virologic diagnosis early in the course of myo-
carditis as it is possible that antivirals would improve the
prognosis. Furthermore, there are case reports of hyperim-
munoglobulin showing an apparent effect in cases of vari-
cella [33], cytomegalovirus [34], and parvovirus [35]
myocarditis. With regard to histologic confirmation, the
Dallas criteria (lymphocyte infiltration with myocyte
necrosis) [36] and more recently the World Heart Federa-
tion criteria (>14 leukocytes/mm2 with necrosis or degen-
eration) [37] have been used for histologic diagnosis, but
the sensitivity and specificity of these criteria are not
known. There are no standardized values for immunohis-
tochemical markers [38]. Our aim in this study was to
analyze reports of use of IVGG for presumed viral myocar-
ditis, but it is possible that many of the patients in the
reports did not have viral myocarditis (only 10 of the 62
patients in the RTC had cellular inflammation on
endomyocardial biopsy). Once our ability to accurately
diagnose viral myocarditis improves, it may be possible to
identify a subset of patients who will respond to IVGG.
This might be patients whose disease was precipitated by
a specific virus, or patients who are treated with IVGG
early in the course of their illness when they have ongoing
viral replication in the myocardium. Perhaps pediatric
patients are more likely to respond. Children are thought
to be more likely to present in the acute inflammatory
stage of illness [16], and may have a worse prognosis than
do adults when they present with fulminant myocarditis
[39,40]
In conclusion, the value of IVGG in patients with acute
myocarditis is obscured by the poor quality of evidence.
We were not able to identify a subgroup of patients who
appear to be more likely to respond to IVGG. A large RCT
is required to evaluate the efficacy of IVGG for acute myo-
carditis with emphasis on the etiology of the myocarditis.
Until there are RCTs demonstrating benefit, use of IVGG
for acute myocarditis should not be part of routine prac-
tice. Moreover, there is a great need for further studies of
the pathophysiology of acute myocarditis, which would
allow for a better understanding of the etiology and the
natural history of the disease. This might allow for
improved diagnostic criteria, which would make it much
easier to design studies of treatment options. This may
also assist in identifying sub-groups of patients where
IVGG or other therapies have a greater potential to confer
clinical benefit.
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